PCOS Just Got a New Name — and It Changes Everything
What the PMOS Rename Means for Women's Health, and Why It's Arriving at the Perfect Moment
May 2026
Last week, a paper published in The Lancet made a quiet announcement with enormous implications: polycystic ovary syndrome — a condition affecting more than 170 million women worldwide — has been officially renamed polyendocrine metabolic ovarian syndrome
(PMOS).
The name change was 14 years in the making. It involved 56 leading academic, clinical, and patient organizations, more than 14,000 survey responses from patients and health professionals around the world, and a rigorous global consensus process. The result is a name that finally says what this condition actually is.
Why the Old Name Was Failing Women
"Polycystic ovary syndrome" has always been a misnomer. The so-called cysts visible on ultrasound aren't pathological cysts at all — they're arrested follicles. More critically, the name collapsed a complex, multisystem condition into the wrong organ. It framed the disorder as primarily gynecological, which meant gynecologists treated the symptoms they could see — irregular cycles, fertility challenges — while the metabolic, endocrine, cardiovascular, dermatological, and psychological dimensions went unaddressed. And too often, unrecognized entirely.
Research estimates that diagnostic delays affected up to 70% of people with the condition. When the name tells the wrong story, the care that follows does, too.
The new name corrects that. PMOS — polyendocrine metabolic ovarian syndrome — names the actual biology:
Polyendocrine acknowledges that multiple interacting hormonal disturbances drive the condition: insulin, androgens, and neuroendocrine hormones — not one rogue ovary.
Metabolic centers, insulin resistance, and cardiometabolic risk are core features, not secondary complications.
Ovarian retains the female reproductive dimension while expanding beyond the narrow confines of the cyst.
Syndrome reflects the full complexity of a multisystem, lifelong condition.
Why This Lands at a Meaningful Moment for HERmedicine
HERmedicine exists because women's health cannot be siloed by organ system. Conditions affecting women — from menopause to metabolic disease to cardiovascular risk — require integrated, multidisciplinary clinical thinking that has historically been absent from their care. PMOS is a case study in what happens when medicine fails to make those connections, and what becomes possible when it does.
This news arrives just weeks before our Women's Health Update on June 19 in Cincinnati — and the faculty assembled for that day speaks directly to every dimension of what PMOS actually involves. Not by coincidence, but because this is exactly the kind of care HERmedicine exists to advance.
The Faculty Who Will Help You Care for This Condition — All of It
The Clinical Framework: Dr. Lisa Larkin, MD, FACP, MSCP, IF — Founder & Executive Director, HERmedicine
HERmedicine was built on the premise that women deserve care that honors the full complexity of their physiology. As a board-certified internist with 34 years of clinical experience and Past President of The Menopause Society, Dr. Larkin brings the integrative lens that PMOS patients have long needed and rarely received. Her June 19 sessions anchor the day: Perimenopause/SWAN, The Winding Road of MHT, and Making Menopause Management Mainstream — because the hormonal disruptions of PMOS don't stop at the ovary, and they don't stop at menopause either.
The Metabolic Picture: Dr. Angela Fitch, MD, FACP, MFOMA, DABOM
The "metabolic" in PMOS isn't incidental — it's foundational. Insulin resistance, visceral adiposity, and cardiometabolic risk are core features of the condition, not downstream complications. Dr. Angela Fitch, Co-Founder and CMO of Knownwell and former faculty at Harvard Medical School, has spent her career making exactly this case. Her June 19 sessions — Metabolic Health & Weight Gain at Midlife and Update on GLP-1s — are directly relevant to anyone managing PMOS patients. Understanding body composition and metabolic phenotype is about meeting this patient where she actually is, not where a BMI chart suggests she is.
The Cardiovascular Dimension: Dr. Martha Gulati, MD, MS, FACC, FAHA
One of the least-discussed consequences of the old PCOS framing is what it obscured about cardiovascular risk. When a condition gets categorized as gynecological, cardiologists aren't in the room. But PMOS patients carry elevated risk for hypertension, dyslipidemia, and cardiovascular disease — risks that accumulate long before midlife. Dr. Martha Gulati, Director of Preventive Cardiology at Cedars-Sinai's Barbra Streisand Women's Heart Center and author of Saving Women's Hearts, has dedicated her career to the cardiovascular health of women that goes unrecognized until it is too late. Her June 19 sessions — CVD Risk Assessment in Women and MHT and CVD: The Data For and Against Primary Prevention — give clinicians the framework to integrate the metabolic and cardiac picture.
The Hormonal and Sexual Health Dimensions: Dr. Sameena Rahman, MD, FACOG, MSCP, IF
The hormonal disruptions at the heart of PMOS — androgen excess, insulin dysregulation, cycle irregularity — have real consequences for sexual health, pelvic health, and quality of life that are consistently undertreated. Dr. Sameena Rahman, board-certified OB/GYN, Menopause Society Certified Practitioner, and ISSWSH Fellow, specializes in exactly these intersections. Her clinical work spans PMOS, PMDD, sexual dysfunction, and chronic pelvic pain. Her June 19 session on Sexual Dysfunction at Midlife — and her participation in the small group case discussions — reflects the reality that this condition affects how women experience their bodies, not just what shows up on their labs.
The Midlife Continuum: Dr. Marla Shapiro, CM, CCFP, MHSc, FRCPC, FCFP, MSCP & Dr. Sabrina Sahni, MD, MSCP
PMOS is a lifelong condition — but what happens to it at perimenopause and menopause? The endocrine and metabolic disruptions don't resolve; in many cases, they intensify as estrogen declines and cardiometabolic risk accelerates. Drs. Shapiro and Sahni bring deep expertise in midlife women's health and the hormonal continuum. Their involvement in the Complex Menopause Management Cases and day-end small-group discussions speaks to the need for clinicians who can follow PMOS patients over decades — not just at diagnosis.
The Primary Care Lens: Dr. Alexa Fiffick, MD, MSCP
Most women with PMOS will first present to a primary care or family medicine clinician, not a specialist. Dr. Alexa Fiffick completed a specialized women's health fellowship at the Cleveland Clinic, where she trained in the conditions most often overlooked by traditional medical education: perimenopause, PMOS, PMDD, hormonal disorders, cardiology, and more. As a concierge family physician and Associate Director of Education for Ms.Medicine, she understands what it takes to translate complex endocrine and metabolic science into whole-patient clinical practice. Her participation in the June 19 small group cases — including Obesity Management and Complex Menopause Management — reflects where comprehensive PMOS care actually starts: in primary care.
What Changes — and What Doesn't
For patients already diagnosed, the answer to "what does this mean for me?" is this: your condition hasn't changed. Your biology is the same. What changes is that the medical world is now more accurately describing what you have — and that should translate, over time, to better understanding from clinicians, more appropriate referral patterns, better-targeted treatment, and less of the "there's nothing wrong with your ovaries" dead ends that have frustrated patients for decades.
For clinicians, the rename signals an update to clinical guidelines, medical education, and international disease classification systems. A global implementation roadmap is underway. But implementation doesn't happen automatically — it happens when clinicians have the education to act on it.
That is what June 19 is for.
Join Us on June 19 in Cincinnati
The Women's Health Update is a full-day, in-person CME event at The Summit Hotel, designed for primary care, OB/GYN, endocrinology, and cardiology clinicians who care for women across the lifespan. Eight AMA PRA Category 1 Credits™. Case-based discussions. Small group sessions on new lipid guidelines, complex menopause management, obesity management, high-risk breast health, and sexual health. Real-time Q&A with faculty who have spent careers at exactly this intersection.
PMOS is polyendocrine. It is metabolic. It is systemic. The clinicians best equipped to manage it are the ones who can hold all of that at once — and that is what this day is built around.
Seats are limited.
